Vor Biopharma (NASDAQ:VOR) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $50.00 price target on the stock.
Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors
Vor Biopharma (NASDAQ:VOR) had its price target lowered by analysts at JPMorgan Chase & Co. from $43.00 to $40.00. They now have an "overweight" rating on the stock.
Vor Biopharma (NASDAQ:VOR) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.